桧烯抗弓形虫活性的体外评价

doi:10.11843/j.issn.0366-6964.2021.010.022

摘要/Abstract

摘要： 本研究旨在筛选具有抗弓形虫活性的萜类化合物，并进行体外活性评价。对26个萜类化合物进行体外抗弓形虫增殖作用的筛选，采用CCK-8法确定活性化合物对Vero细胞的毒性和安全浓度，Giemsa染色进一步确定对弓形虫的活性，通过细胞免疫荧光、Giemsa染色和生物化学发光法评价活性化合物对弓形虫的体外活性。结果表明，26个萜类化合物中，桧烯对弓形虫有显著的活性，桧烯对RH-2F的IC₅₀为90.76 μg·mL^-1，Giemsa染色和细胞免疫荧光的结果表明，桧烯对细胞内的两种弓形虫虫株都有显著的抗增殖作用，并且对弓形虫的入侵有极显著的抑制作用（P<0.001）。综上表明，桧烯对弓形虫的入侵和细胞内增殖具有显著的抑制作用，可作为潜在的抗弓形虫先导化合物。

关键词: 弓形虫, 萜类化合物, 莪术烯, 环黄芪醇, 桧烯

Abstract: This study aimed at screening terpenoids with anti-Toxoplasma gondii activity and evaluating their activity in vitro. The activity of 26 terpenoids against Toxoplasma gondii (T. gondii) in vitro was screened. The toxicity and safe concentration of these active compounds to Vero cells were determined by CCK-8 kit. The activity against T. gondii was further identified by Giemsa staining. The activity of the active compounds against T. gondii in vitro was evaluated by cell immunofluorescence, Giemsa staining and biochemical luminescence method. The results showed that among the 26 terpenoids, sabinene had a significant activity against T. gondii. The IC₅₀ of sabinene to RH-2F was 90.76 μg·mL^-1. The results of Giemsa staining and cellular immunofluorescence showed that sabinene had significant anti-proliferative effect on two intracellular strains of T. gondii and had a very significant inhibitory effect on the invasion of T. gondii (P<0.001). It has been found that sabinene had a significant inhibitory effect on the invasion and intracellular proliferation of T. gondii, and can be used as a potential lead compound against T. gondii.

Key words: Toxoplasma gondii, terpenoids, curzerene, astramembrangenin, sabinene

中图分类号:

S859.795

邱燕华, 翟斌涛, 尚小飞, 周绪正, 李冰, 张继瑜. 桧烯抗弓形虫活性的体外评价[J]. 畜牧兽医学报, 2021, 52(10): 2915-2923.

QIU Yanhua, ZHAI Bintao, SHANG Xiaofei, ZHOU Xuzheng, LI Bing, ZHANG Jiyu. Evaluation of the Activity of Sabinene against Toxoplasma gondii in vitro[J]. Acta Veterinaria et Zootechnica Sinica, 2021, 52(10): 2915-2923.

参考文献 33

[1]	ALMERIA S, DUBEY J P. Foodborne transmission of Toxoplasma gondii infection in the last decade. An overview[J]. Res Vet Sci, 2021, 135:371-385.
[2]	高俊莹, 张东超, 李璇, 等. 弓形虫表面抗原SAG1黏附宿主细胞表面硫化肝素的特性研究[J]. 畜牧兽医学报, 2019, 50(9):1874-1881.GAO J Y, ZHANG D C, LI X, et al. The characteristic study of Toxoplasma gondii surface antigen SAG1 adhering to heparan sulfate on the host cell surface[J]. Acta Veterinaria et Zootechnica Sinica, 2019, 50(9):1874-1881. (in Chinese)
[3]	MILNE G, WEBSTER J P, WALKER M. Toxoplasma gondii:an underestimated threat?[J]. Trends Parasitol, 2020, 36(12):959-969.
[4]	ELSHEIKHA H M, MARRA C M, ZHU X Q. Epidemiology, pathophysiology, diagnosis, and management of cerebral toxoplasmosis[J]. Clin Microbiol Rev, 2020, 34(1):e00115-19.
[5]	ALDAY P H, DOGGETT J S. Drugs in development for toxoplasmosis:advances, challenges, and current status[J]. Drug Des Devel Ther, 2017, 2017:273-293.
[6]	FENG X C, CAO S J, QIU F, et al. Traditional application and modern pharmacological research of Artemisia annua L[J]. Pharmacol Ther, 2020, 216:107650.
[7]	CHOI W H, LEE I A. The mechanism of action of ursolic acid as a potential anti-Toxoplasmosis agent, and its immunomodulatory effects[J]. Pathogens, 2019, 8(2):61.
[8]	OLIVEIRA C B S, MEURER Y S R, MEDEIROS T L, et al. Anti-Toxoplasma activity of estragole and thymol in murine models of congenital and noncongenital toxoplasmosis[J]. J Parasitol, 2016, 102(3):369-376.
[9]	GOZALBES R, GÁLVEZ J, GARCíA-DOMENECH R, et al. Molecular search of new active drugs against Toxoplasma gondii[J]. SAR QSAR Environ Res, 1999, 10(1):47-60.
[10]	ZHANG H B, LIU Q, CAO Y J, et al. Microbial production of sabinene-a new terpene-based precursor of advanced biofuel[J]. Microb Cell Fact, 2014, 13:20.
[11]	SI H F, XU C Y, ZHANG J L, et al. Licochalcone A:an effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo[J]. Int J Parasitol:Drugs Drug Resist, 2018, 8(2):238-245.
[12]	QIAN W F, WANG H, SHAN D, et al. Activity of several kinds of drugs against Neospora caninum[J]. Parasitol Int, 2015, 64(6):597-602.
[13]	ZHANG J L, SI H F, LI B, et al. Myrislignan exhibits activities against Toxoplasma gondii RH strain by triggering mitochondrial dysfunction[J]. Front Microbiol, 2019, 10:2152.
[14]	JANETKA J W, HOPPER A T, YANG Z P, et al. Optimizing pyrazolopyrimidine inhibitors of calcium dependent protein kinase 1 for treatment of acute and chronic toxoplasmosis[J]. J Med Chem, 2020, 63(11):6144-6163.
[15]	MURAKOSHI F, BANDO H, SUGI T, et al. Nullscript inhibits Cryptosporidium and Toxoplasma growth[J]. Int J Parasitol:Drugs Drug Resist, 2020, 14:159-166.
[16]	HAN Y M, ADEYEMI O S, KABIR M H B, et al. Screening of compound libraries for inhibitors of Toxoplasma growth and invasion[J]. Parasitol Res, 2020, 119(5):1675-1681.
[17]	LU Y N, ZHAO X D, XU X, et al. Arctigenin exhibits hepatoprotective activity in Toxoplasma gondii-infected host through HMGB1/TLR4/NF-κB pathway[J]. Int Immunopharmacol, 2020, 84:106539.
[18]	LI J X, GUO H P, GALON E M, et al. Hydroxylamine and carboxymethoxylamine can inhibit Toxoplasma gondii growth through an aspartate aminotransferase-independent pathway[J]. Antimicrob Agents Chemother, 2020, 64(3):e01889-19.
[19]	GUO H P, GAO Y, JIA H L, et al. Characterization of strain-specific phenotypes associated with knockout of dense granule protein 9 in Toxoplasma gondii[J]. Mol Biochem Parasitol, 2019, 229:53-61.
[20]	SMITH N C, GOULART C, HAYWARD J A, et al. Control of human toxoplasmosis[J]. Int J Parasitol, 2021, 51(2-3)95-121.
[21]	RADKE J B, BURROWS J N, GOLDBERG D E, et al. Evaluation of current and emerging antimalarial medicines for inhibition of Toxoplasma gondii growth in vitro[J]. ACS Infect Dis, 2018, 4(8):1264-1274.
[22]	ROSENBERG A, LUTH M R, WINZELER E A, et al. Evolution of resistance in vitro reveals mechanisms of artemisinin activity in Toxoplasma gondii[J]. Proc Natl Acad Sci U S A, 2019, 116(52):26881-26891.
[23]	WANG D W, XING M G, El-ASHRAM S, et al. Determination of lumefantrine as an effective drug against Toxoplasma gondii infection-in vitro and in vivo study[J]. Parasitology, 2021, 148(1):122-128.
[24]	YAMAMOTO M, ICHINOHE T, WATANABE A, et al. The antimalarial compound Atovaquone inhibits zika and dengue virus infection by blocking E protein-mediated membrane fusion[J]. Viruses, 2020, 12(12):1475.
[25]	KHALID A, TAKAGI H, PANTHEE S, et al. Development of a terpenoid-production platform in Streptomyces reveromyceticus SN-593[J]. ACS Synth Biol, 2017, 6(12):2339-2349.
[26]	CAO Y J, ZHANG H B, LIU H, et al. Biosynthesis and production of sabinene:current state and perspectives[J]. Appl Microbiol Biotechnol, 2018, 102(4):1535-1544.
[27]	RYU Y, LEE D, JUNG S H, et al. Sabinene prevents skeletal muscle atrophy by inhibiting the MAPK-MuRF-1 pathway in rats[J]. Int J Mol Sci, 2019, 20(19):4955.
[28]	PARK B I, KIM B S, KIM K J, et al. Sabinene suppresses growth, biofilm formation, and adhesion of Streptococcus mutans by inhibiting cariogenic virulence factors[J]. J Oral Microbiol, 2019, 11(1):1632101.
[29]	ZHOU S X, WEI C X, ZHANG C, et al. Chemical composition, phytotoxic, antimicrobial and insecticidal activity of the essential oils of Dracocephalum integrifolium[J]. Toxins, (Basel), 2019, 11(10):598.
[30]	VIMAL A, PAL D, TRIPATHI T, et al. Eucalyptol, sabinene and cinnamaldehyde:potent inhibitors of salmonella target protein L-asparaginase[J]. 3 Biotech, 2017, 7(4):258.
[31]	GUO J, COKER A R, WOOD S P, et al. Structure and function of the thermostable L-asparaginase from Thermococcus kodakarensis[J]. Acta Crystallogr D Struct Biol, 2017, 73(Pt 11):889-895.
[32]	CACHUMBA J J M, ANTUNES F A F, PERES G F D, et al. Current applications and different approaches for microbial L-asparaginase production[J]. Braz J Microbiol, 2016, 47(Suppl 1):77-85.
[33]	ZHANG Y, LAI B S, JUHAS M. Deactivation and mislocalization of Toxoplasma gondii rhoptry protein 18 induced by a single amino acid mutation on the proton transport catalytic aspartic acid[J]. Microbiol Res, 2020, 230:126352.